ABSTRACT -The main focus of this study was to determine the optimal administration period concerning the toxic effects on ovarian morphological changes in the repeated dose toxicity study. In order to assess the morphological and functional changes induced in the ovary by cyclophosphamide (CP), the compound was administrated to female rats at dose levels of 0, 5, 10 and 20 mg/kg for the repeated dose toxicity study for 2 or 4 weeks, and at 0, 5, 10, and 20 mg/kg for the female fertility study from 2 weeks prior to mating to Day 7 of pregnancy. In the repeated dose toxicity study, increases in large sized atretic follicles, atrophy of corpora lutea were observed in the 20 mg/kg group in the 4-week study by the histopathological examination of the ovaries. There were no drug-related changes in the ovary in the 2-week study. In the female fertility study, the numbers of implantation were slightly decreased and the corpora lutea of pregnancy was not observed in the 20 mg/kg group. The dose-dependent increase in the incidence of post-implantation loss was observed, and no abnormalities were observed in the estrus cycle and -tant endpoints for the evaluation of drug-induced ovarian damage as well as caesarean section. In conclutoxicity study.
INTRODUCTION
As a part of a collaborative study on the toxicity related to female fertility, we performed experiments using cyclophosphamide (CP), an alkylating agent commonly used in combination with cancer chemotherapy regimens. An earlier study demonstrated that a high dose of CP induced a depletion of the ovarian follicles in rats, which suggested the primary target of toxicity was the ovarian follicle (Mattinson et al., 1983) . The same group of investigators have shown in the same strain of rats that intraperitoneal treatment with a high dose of CP resulted in a loss of the medium-large follicles when the drug was administrated chronically (Shiromizu et al., 1984) . In addition, the antineoplastic alkylating agent CP is known to impair female reproductive function (Ataya and Ramahi-Ataya, 1993; Tanaka et al., 1992) . There were a number of reports on the effects of this drug on fertility.
However, there were no reports on collaborative study on toxicity-related female fertility.
The present study was designed to determine whether 2-or 4-week administration periods for detecting histopathological changes in a repeated-dose toxicity study to compare the potential ovarian toxicity with the female reproductive function in a fertility study. general toxicity and female fertility studies were purchased from Charles River Laboratories Japan, Inc. (Shiga, Japan). The animals were housed in a room maintained at 23°C ± 2°C with 60% ± 10% relative humidity, and lighting was maintained for 12 hr daily. All animals were allowed free access to commercial rodent chow, CRF-1 (Oriental Yeast Co., Ltd., Tokyo, Japan) and to tap water. All experimental procedures were performed in accordance with the In-house Guidelines for the Animal Care and Use of Otsuka Pharmaceutical Co., Ltd..
Study designs
Repeated-dose toxicity studies CP was orally administered to the female rats at dose levels of 0, 5, 10 and 20 mg/kg for 2 and 4 weeks. For each study period (2 weeks and 4 weeks), 3 groups of 10 animals per group, and 1 group of 9 animals were used. The general conditions of all animals were observed once or twice (prior to and after the dosing) daily during the dosing period. The body weight of each animal was measured before the dosing on Day 1, and once or twice weekly during the dosing period in the 2-weeks and 4-weeks studies. Estrous cycles were determined everyday by vaginal smear in the last 1 week of the 2-week study or in the last 2-week of the 4-week study. On the day of necropsy, all of the animals were anesthetized with ether and blood was exsanguinated from the abdominal aorta. After exsanguination, the ovaries (right and left) and uteruses were weighted and the ovaries (right and left), uteruses -topathological specimens were prepared and stained with hematoxylin and eosin (HE) according to standard procedures. In the dissection, the bilateral ovaries were transversally halved to observe the maximum area of the ovary using a light microscopy. To the ovaries, immunohistochemistry using Dako anti-Proliferation cell nuclear antigen (PCNA) antibody (clone: PC10) was also performed. The prepared histopathological specimens were examined was referred to Pedersen and Peters (1968) .
Female fertility study
CP was orally administered to the female rats at dose levels of 0, 5, 10 and 20 mg/kg for 2 weeks before mating. All groups consisted of 10 animals of each sex. The males were nonttreated and used only for mating purpose. After the 2 weeks of administration, the females were cohabited with the non-treated males for up to 4 days CP or sterilized water was continued through the mating period and until Day 7 of pregnancy. The general conditions of all females were observed twice (prior to and just after the dosing) daily during the dosing period and once daily after the dosing period. Before mating, the females were weighed twice weekly. The maternal animals were weighed on Days 0 to 7 and 13 of pregnancy. In addition, a vaginal smear was collected from each female during the pre-mating period, and the estrous cycle was evaluated. Cesarean section was performed on Day 13 of pregnancy and then the dams were necropsied and the major internal organs were examined macroscopically. Then the numbers of corpora lutea, implantations, live and dead embryos were counted, and the copulation rate and fertility rate were calculated.
Statistical analyses
During the dosing period, the following data was analyzed by one-way analysis of variance; body weight and body weight gain, organ weight (absolute and relative to body weight), the number of corpora lutea, implantation, early and late deaths; the total number of deaths and the difference between was found in the one-way analysis of variance, the Dunnett's test was used to analyze the difference of the control and treated group.
The duration of pairing; incidences of early and late death, pre-and post-implantation losses were analyzed by the Dunnett's test using rank transformation when any Wallis test homogeneity of variance.
Incidence of abnormal estrus cycles, copulation index, fertility index were analyzed by the Fisher-Irwin test to examine the differences between the control and each treated group.
RESULTS

Repeated dose toxicity studies
During the dosing period, no animal died and there were no drastic changes in the general condition in any of the groups treated with CP in the 2-week or 4-week study.
gain (base: Day 1) were observed in the 10 and 20 mg/kg groups (Tables 1 and 2) .
As for the estrous cycle, no animals showed any abnormal estrus cycles during the 2-week in study. An animal in the 5 mg/kg group and 2 animals in the 20 mg/kg group showed abnormal estrous cycles in 4-week study (Tables 1 and 2 ). changes in the 2-week study (Table 3) . After 4 weeks of the right ovary, left ovary and uterus were observed in the 20 mg/kg group (Table 4) . Macroscopically, the corpus when compared to those in the control group.
In the histopathological examination, there were no significant changes in the 2-week study. Abnormalities were detected in the ovary, uterus and vagina in the 4- 0 /10 0 /10 0 /10 0 /10 1) Irregular cycle means interval between estrous cycle was longer than 4 days, or anestrous. week study (Table 5 ). Slight atrophy of the corpora lutea were observed in the right and left ovaries of 6 animals in the 20 mg/kg group (Figs. 1A and B) . Slight increases in the atretic follicles were observed in 2 animals of the 20 mg/kg group in the 4-week study. In these animals, (1968) , were increased in the 20 mg/kg group as compared to those of the control group (Figs. 2C and D ). There were any differences of small or medium follicles in the treated groups from those in the control group. -lium of the vagina were observed in 2 animals of the 20 mg/kg group after 4 weeks of treatment.
Female fertility study
For the effects on the dams, stains around the nose and swelling of the limbs were observed in one animal of the 20 mg/kg group. The body weights and food consumptions were decreased during the pre-mating and gestational periods in the 20 and 10 mg/kg groups. At necropsy, small thymus, large adrenal gland and spleen were observed in the 20 mg/kg group (Table 6) .
For effects on fertility and early embryonic development, the number of the corpora lutea could not be examined in the 20 mg/kg group, because the corpora lutea of pregnancy were not observed. The number of implantation was slightly decreased and all embryos were absorbed in the early stage of pregnancy in this group.
In the 10 mg/kg group, the number of the corpora lutea and the incidence of pre-implantation loss were slightly increased. Most embryos were absorbed in the early stage of pregnancy and the incidence of post-implantation was markedly increased.
In the 5 mg/kg group, the incidence of pre-implantation loss and number of corpora lutea were slightly increased. The number of early deaths and incidence of post-implantation loss were slightly increased (Table 6 ).
DISCUSSION
CP is an alkylating agent commonly used in combination with cancer chemotherapy regimens. In this collaborative work, we used CP to determine the optimal administration period concerning the effects on the ovarian morphological changes in the repeated-dose toxicity study. In addition, the non observable adverse effect level for the repeated-dose toxicity study focused on the ovary and for the female fertility study were also compared.
In the 2-week study, repeated-dose toxicity study, significant decreases in the body weight and body weight gain were observed in the 5 mg/kg and higher dosage groups although there were no drug-related changes in ovarian toxicity at the necropsy, and no drug-related changes in the organ weight and ovary in the pathological examination. 
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In the 4-week, repeated-dose toxicity study, significant decreases in body weight and body weights gain were observed in the 10 mg/kg and higher dosage groups. Decreases in the absolute ovary (right, left) weights were observed in the 20 mg/kg group. In histopathology, atrophy of the corpra lutea in the right and left ovaries was observed in 6 females of the 20 mg/kg group, although on the small or medium follicles. While the mechanism of this action remained to be determined, our results indicated that CP might affect the corpora lutea as an ovarian toxicant. The previous studies have reported that a decrease in the volume of corpora lutea were observed in CP-treated (500 mg/kg i.p.) mice (Plowchalk et al., 1992) , and that decreases in the numbers of corppora lutea was observed in CP-treated (500 mg/kg i.p.) rats (Jarrell et al., 1987) , supporting our results.
In the ovary of the 4-week study, increases in the large atretic follicles were also observed in 2 females of the 20 mg/kg group. This result might be related with any effects of this compound on the ovarian function. This data suggested that CP might induce toxicity of follicular growth. Increases in the atretic follicles were observed in many drug included CP (Jarrell et al., 1987) . the vagina and abnormal estrous cycle were observed in a small number of animals of the 20 mg/kg group. It was possibile that these changes were secondary effects due to the decrease in the body weight,and any effet on the ovary might be induced by the treatment. Further investigation should be necessary. In the female fertility study, the number of corpora lutea of pregnancy was not observed in the 20 mg/kg group, but was slightly increased in the 5 and 10 mg/kg groups. Since CP caused the atrophy of the corpora lutea in the 20 mg/kg group in the 4-week toxicity study, CP would also excert some effect on the corpora lutea in this study.
The number of implantation was decreased in the 20 mg/kg group, but there was no decrease in the number in the 5 and 10 mg/kg groups. Since the number of implantation of the 5 and 10 mg/kg groups were comparable to that of the control group, the increased incidence of preimplantation loss was contributed to the increase. In cases that the ovulation number was considerably increased, the spacing effect in the uterus allowed only the normal numbers of implantation and pre-implantation loss was increased (Wise et al ., 2008) . The number of live embryos were decreased and the number of resorptions increased in a dose-related manner. The dose-dependent increased incidence of the post-implantation loss would be related to the embryonic lethal action of CP.
These studies were designed to determine detecting ovarian morphological changes in the repeated-dose tox--icity study focused on the ovary with the female fertility parameters in the female fertility study. As a result, in the repeated-dose toxicity study, increases in the atretic follicles, atrophy of the corpora lutea were observed in the 20 mg/kg group in the 4-week study, by the histopathological examination of the ovaries (no observable adverse effect level for the ovaries: 10 mg/kg). There were no drug-related changes in the ovary in 20 the mg/kg group in the 2-week study. In the fertility study, especially toxicity to the corpora lutea, such as disappearance of corpora lutea of pregnancy was observed in the 20 mg/kg group. In conclusion, the 4-week administration period was sufdose toxicity study.
In conclusion, CP stimulated the corpora lutea and the embryonic lethal action, and the ovarian histopathological of the female fertility study. Thus the altered ovarian morphology was one of the most important end opoints for detecting CP in the ovary, and a 4-week repeated-dose toxicity study was considered to be plausible for detecting the ovarian toxicity of CP, although it was not detectable in the 2-week repeated-dose toxicity.
